ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.111,66
0,21%
S&P 500
5.483,43
0,19%
Dow Jones
38.856,34
0,20%
Euro vs US Dollar
1,07339
-0,06%
Bitcoin
64.804,18
-2,53%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Kezar Life Sciences Inc (KZR)

  7. Kezar Life Sciences Inc (KZR) News

KZR

Kezar Life Sciences (KZR)

Kezar Life Sciences Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KZR
DatumZeitQuelleÜberschriftSymbolFirma
07/06/202423h59Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
04/06/202422h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
29/05/202422h01Business WireKezar Life Sciences to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:KZRKezar Life Sciences Inc
09/05/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
09/05/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
09/05/202422h01Business WireKezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
06/05/202422h05Business WireKezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
08/04/202422h01Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
14/03/202421h01Business WireKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
08/03/202422h05Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
28/02/202422h01Business WireKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:KZRKezar Life Sciences Inc
27/02/202400h30Business WireEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisNASDAQ:KZRKezar Life Sciences Inc
14/02/202412h50Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KZRKezar Life Sciences Inc
17/01/202423h09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
09/01/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
08/01/202414h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
04/12/202322h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
21/11/202322h01Business WireKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:KZRKezar Life Sciences Inc
13/11/202322h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
13/11/202322h01Business WireKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:KZRKezar Life Sciences Inc
09/11/202322h25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KZRKezar Life Sciences Inc
03/11/202321h03Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
27/10/202322h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
09/10/202323h56Business WireKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:KZRKezar Life Sciences Inc
03/10/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KZRKezar Life Sciences Inc
03/10/202322h10Business WireKezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive OfficerNASDAQ:KZRKezar Life Sciences Inc
21/09/202302h30Dow Jones NewsStocks to Watch: FedEx, Kezar Life Sciences, TranscatNASDAQ:KZRKezar Life Sciences Inc
21/09/202300h30Business WireKezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast AsiaNASDAQ:KZRKezar Life Sciences Inc
31/08/202322h01Business WireKezar Life Sciences to Participate in Three Upcoming Investor ConferencesNASDAQ:KZRKezar Life Sciences Inc
10/08/202322h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KZRKezar Life Sciences Inc
 Showing the most relevant articles for your search:NASDAQ:KZR

Kürzlich von Ihnen besucht

CCOM
US500
US 500
TG
DBK
Deutsche Bank
DBI
MDAX
MDAX
TG
RHM
Rheinmetall
PM
XAUUSD
Gold vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
FX
EURUSD
Euro vs US Dollar
NASDAQ
QQQ
Invesco QQQ Trust Series 1
TG
MBG
MercedesBenz
NYSE
MRK
Merck
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
NASDAQ
TSLA
Tesla
TG
DTE
Deutsche Telekom
AMEX
XLF
Financial Select Sector
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten